On Tuesday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), remained unchanged to $1.80, hitting its lowest level.
Advanced Micro Devices, declared that Senior Vice President and Chief Technology Officer Mark Papermaster will present at the Pacific Crest 17th Annual Global Technology Leadership Forum at 10 a.m. MDT on Monday, Aug.10, 2015 in Vail, Colorado.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Novavax, Inc. (NASDAQ:NVAX), declined -0.88% to $12.32, during its last trading session, hitting its highest level.
Novavax, declared positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in noteworthyantigen dose-sparing.
The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points counting days 28 and 35.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Finally, Agilent Technologies Inc. (NYSE:A), ended its last trade with -1.22% loss, and closed at $39.57.
Agilent Technologies, declared that Dr. Lawrence J. Lesko has received an Agilent Thought Leader Award in support of his research into preclinical toxicological assessments of new medicines.
An internationally recognized pharmacologist, Dr. Lesko directs the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s College of Pharmacy in Orlando.
Dr. Lesko and his team are using Agilent accurate mass Q-TOF LC/MS to collect and analyze metabolomics data. With the assist of Agilent’s Mass Profiler Professional and Pathway Architect software, they hope to discover biomarker panels that could enable the development of future companion diagnostics.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
